Biogen and Elan shares fall after new reports of PML with Tysabri
This article was originally published in Scrip
Executive Summary
Two further cases of progressive multifocal leucoencephalopathy (PML) have been confirmed in patients receiving Biogen Idecand Elan's multiple sclerosis therapy Tysabri (natalizumab), causing both companies' share prices to fall sharply.